• Article / Chapter
  • Regorafenib in glioblastoma recurrence: how to deal with conflicting 'real-life'...

Regorafenib in glioblastoma recurrence: how to deal with conflicting 'real-life' experiences?

GND
129682543
Affiliation
Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Nordrhein-Westfalen, Germany.
Glas, Martin;
GND
1035782421
ORCID
0000-0002-0678-5852
Affiliation
Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Kebir, Sied

Preview

Category

Date Issued:
16.12.2019
URN:
urn:nbn:de:hbz:464-20200527-143612-4
DOI:
10.1177/1758835919887667
Language:
English
Type of Resource:
Text
Collection:
E-Publications
Subject categories of the Deutsche Nationalbibliografie:
610 Medical sciences Medicine
Hosting institution:
Faculty of Medicine, Essen University Hospital, Clinic for Neurology
Hosting institution:
Faculty of Medicine, Essen University Hospital, Westdeutsches Tumorzentrum Essen e.V. (WTZE)
funding:
The publication of this article was supported by the Publication Fund of the University of Duisburg-Essen.
Info on primary publication:
Ther Adv Med Oncol 2019, Vol. 11: 1–2 ; First Published December 16, 2019

Cite

Citation style:
Glas, M., Kebir, S., 2019. Regorafenib in glioblastoma recurrence: how to deal with conflicting “real-life” experiences? https://doi.org/10.1177/1758835919887667
Could not load citation form.

Rights

Use and reproduction:
This work may be used under a
CC BY-NC 4.0 LogoCreative Commons Attribution - NonCommercial 4.0 License (CC BY-NC 4.0)
.

Export

BibTeX, MODS, MARCXML, RIS, ISI, PICA, CSV, DC